Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics

An isolated recombinant human antibody that specifically binds CD46 and is internalized, via macropinocytosis, into a cell expressing or overexpressing CD46, wherein:

• said isolated recombinant human antibody specifically binds cells that express or overexpress a CD46, and wherein said isolated recombinant human antibody specifically binds to the same or an overlapping epitope as the antibodies:
• YS5 (represented by SEQ ID NOs:
• 1 and 22), YS5F (represented by SEQ ID NOs:
• 2 and 23), YS5v1D (represented by SEQ ID NOs:
• 3 and 24), SB1HGNY (represented by SEQ ID NOs:
• 4 and 25), YS12 (represented by SEQ ID NOs:
• 5 and 26), 3G7RY (represented by SEQ ID NOs:
• 6 and 27), YS6 (represented by SEQ ID NOs:
• 7 and 28), YS1 (represented by SEQ ID NOs:
• 8 and 29), YS3 (represented by SEQ ID NOs:
• 9 and 30), YS4 (represented by SEQ ID NOs:
• 10 and 31), YS8 (represented by SEQ ID NOs:
• 11 and 32), YS7 (represented by SEQ ID NOs:
• 12 and 33), YS9 (represented by SEQ ID NOs:
• 13 and 34), YS10 (represented by SEQ ID NOs:
• 14 and 35), YS11 (represented by SEQ ID NOs:
• 15 and 36), 3G7HY (represented by SEQ ID NOs:
• 16 and 37), 3G7NY (represented by SEQ ID NOs:
• 17 and 38), 3G7 (represented by SEQ ID NOs:
• 18 and 39), SB2 (represented by SEQ ID NOs:
• 19 and 40), 2C8 (represented by SEQ ID NOs:
• 20 and 41), [[and/]]or UA8kappa (represented by SEQ ID NOs:
• 21 and 42).